Jason Firdette, Senior VP of Investor Relations and Corporate Communications, Mersana: Yeah. I’ll take that. So, so this yes. STING agonist, HER2, ADC, that we are in dose escalation with.

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation ... a discontinued ADC candidate. General and ...

an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media ...

The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms ... STING activation data related to XMT-2056; Mersana’s collaborations with ...

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted ...

On today's call, we have Mersana's Chief Executive Officer ... 2056 is our immunosynthen STING agonist ADC targeting a novel epitope of HER2. Later in 2025, we plan to present initial ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Martin Huber; President, Chief Executive Officer, Director; Mersana Therapeutics Inc Brian Deschuytner; Chief Financial Officer, Chief Operating Officer, Senior Vice President; Mersana Therapeutics ...